|
Preclinical evaluation of XPO1 inhibition in Wilms tumors. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - DarwinHealth; regeneron; Teva |
Honoraria - Shanghai Cell Therapy Group; Xiamen Enchang Group |
Consulting or Advisory Role - Abbvie; DarwinHealth |
Patents, Royalties, Other Intellectual Property - The technology developed by my lab, including ARACNe, VIPER, OncoTreat/OncoTarget, MINDy, and DEMAND were licensed exclusively to DarwinHealth, Inc. Columbia receives royalties from these licenses and both my lab and I share a portion of these roylaties |
Travel, Accommodations, Expenses - Abbvie; DarwinHealth |
|
|
No Relationships to Disclose |
|
|
Stock and Other Ownership Interests - Imago Pharma; Isabl Technologies |
Consulting or Advisory Role - DarwinHealth; Emendo; Imago Pharma; Karyopharm Therapeutics |
Patents, Royalties, Other Intellectual Property - Royalty from licensing agreements with MI Bioresearch |